Clinical trials
Diabetes Mellitus, Type 2 trials in Taiwan with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 1 |
| 2013 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 30 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Taipei Veterans General Hospital, Taiwan | 5 |
| National Taiwan University Hospital | 4 |
| Chang Gung Memorial Hospital | 3 |
| Min-Sheng General Hospital | 2 |
| National Cheng-Kung University Hospital | 2 |
| Taipei Medical University WanFang Hospital | 2 |
| Chang Gung University of Science and Technology | 1 |
| Chimei Medical Center | 1 |
| China Medical University Hospital | 1 |
| Fooyin University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 30 |
| Diabetes Mellitus | 5 |
| Hyperglycemia | 3 |
| Coronary Artery Disease | 2 |
| Insulin Resistance | 2 |
| Atherosclerosis | 1 |
| Diabetic Nephropathies | 1 |
| Diabetic Neuropathies | 1 |
| Endocrine System Diseases | 1 |
| Glucose Metabolism Disorders | 1 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.